Intercept Pharmaceuticals (NASDAQ:ICPT) Rating Increased to Hold at ValuEngine

Intercept Pharmaceuticals (NASDAQ:ICPT) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday, ValuEngine reports.

ICPT has been the topic of several other research reports. Oppenheimer lowered their price target on shares of Intercept Pharmaceuticals from $175.00 to $170.00 in a report on Monday, April 29th. Stifel Nicolaus started coverage on shares of Intercept Pharmaceuticals in a report on Monday, June 24th. They issued a “hold” rating and a $89.00 price target on the stock. Wells Fargo & Co raised shares of Intercept Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $90.02 price target on the stock in a report on Thursday, May 2nd. Zacks Investment Research raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $73.00 price target on the stock in a report on Monday, July 15th. Finally, BidaskClub lowered shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 26th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and sixteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $142.00.

NASDAQ:ICPT traded down $0.13 during trading hours on Thursday, hitting $62.81. 519,844 shares of the company traded hands, compared to its average volume of 701,471. The company has a market capitalization of $1.87 billion, a PE ratio of -5.78 and a beta of 1.33. Intercept Pharmaceuticals has a twelve month low of $60.90 and a twelve month high of $133.74. The stock’s 50-day moving average price is $74.15. The company has a debt-to-equity ratio of 19.41, a current ratio of 3.72 and a quick ratio of 3.72.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.57) by ($0.46). The company had revenue of $52.25 million for the quarter, compared to analyst estimates of $52.15 million. Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. Intercept Pharmaceuticals’s revenue for the quarter was up 45.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($3.22) earnings per share. On average, analysts expect that Intercept Pharmaceuticals will post -10.05 EPS for the current year.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 595 shares of the stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $78.66, for a total transaction of $46,802.70. Following the sale, the insider now owns 20,452 shares of the company’s stock, valued at approximately $1,608,754.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Luca Benatti acquired 1,200 shares of the firm’s stock in a transaction on Tuesday, May 14th. The shares were bought at an average cost of $83.50 per share, for a total transaction of $100,200.00. Following the acquisition, the director now owns 7,556 shares in the company, valued at $630,926. The disclosure for this purchase can be found here. 5.00% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the business. Financial Gravity Wealth Inc. bought a new stake in Intercept Pharmaceuticals during the 1st quarter worth about $33,000. AdvisorNet Financial Inc bought a new stake in Intercept Pharmaceuticals during the 2nd quarter worth about $56,000. Advisor Group Inc. grew its holdings in Intercept Pharmaceuticals by 63.5% during the 4th quarter. Advisor Group Inc. now owns 739 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 287 shares during the last quarter. Botty Investors LLC bought a new stake in Intercept Pharmaceuticals during the 1st quarter worth about $84,000. Finally, Coastal Investment Advisors Inc. grew its holdings in Intercept Pharmaceuticals by 124.9% during the 2nd quarter. Coastal Investment Advisors Inc. now owns 1,417 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 787 shares during the last quarter. 76.44% of the stock is currently owned by hedge funds and other institutional investors.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

See Also: What are no-load funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.